EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC)

Yuchen Zhang, Lexian Tong, Fangjie Yan, Ping Huang, Cheng-Liang Zhu, Chenghao Pan

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2024.107394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Yuchen Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang U…. Hauptthemen laut MEDLINE: ErbB Receptors, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) is one of the most studied drug targets for treating non-small-cell lung cancer (NSCLC). However, there are no approved inhibitors for the C797S resistance mutation caused by the third-generation EGFR inhibitor (Osimertinib). Therefore, the development of fourth-generation EGFR inhibitors is urgent. In this study, we clarified the structure-activity relationship of several synthesized compounds as fourth-generation inhibitors against human triple (Del19/T790M/C797S) mutation. Representative compound 52 showed potent inhibitory activity against EGFRL858R/T790M/C797S with an IC50 of 0.55 nM and significantly inhibited the proliferation of the Ba/F3 cell line harboring EGFRL858R/T790M/C797S with an IC50 of 43.28 nM. Moreover, 52 demonstrated good pharmacokinetic properties and excellent in vivo efficacy. Overall, the compound 52 can be considered a promising candidate for overcoming EGFR C797S-mediated mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsCarcinoma, Non-Small-Cell LungAntineoplastic AgentsLung NeoplasmsAcrylamidesProtein Kinase InhibitorsAniline CompoundsCell ProliferationDrug DesignDrug Screening Assays, AntitumorDrug Resistance, NeoplasmDose-Response Relationship, DrugHumansStructure-Activity RelationshipMolecular StructureAnimalsMiceCell Line, TumorMutationIndolesPyrimidines

Stichwörter der Autor:innen

EGFRNSCLCStructure-activity relationshipTriple mutation

Substanzen

ErbB ReceptorsAntineoplastic AgentsAcrylamidesProtein Kinase InhibitorsAniline CompoundsIndolesPyrimidinesosimertinibEGFR protein, human

Autor:innen und Institutionen

  • Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR China; Innovation Institute for Artific…
  • Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou 310018, PR China.
  • Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, PR China; Key Laboratory of Endocr…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Tong, L., Yan, F., Huang, P., Zhu, C. L., & Pan, C. (2024). Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC). Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107394

Vancouver

Zhang Y, Tong L, Yan F, Huang P, Zhu CL, Pan C. Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC). Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107394

BibTeX
@article{Zhang2024,
  author = {Zhang, Yuchen and Tong, Lexian and Yan, Fangjie and Huang, Ping and Zhu, Cheng-Liang and Pan, Chenghao},
  title = {Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC)},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2024.107394}
}
Kostenlos starten →